BIOSPECTATOR: RudaCure, 'Rac1 inhibitor' traitement de la sécheresse oculaire — "Domestic Phase 1 trial in H2"
le PDG Yongho Kim of RudaCure a déclaré : "Our traitement de la sécheresse oculaire candidate, the Rac1 inhibitor 'RCI001 (8-oxo-2'-deoxyguanosine),' showed significatif récupération des lésions cornéennes and increased sécrétion lacrymale compared to the control drug from day 5 of administration in mouse model studies, with aucun effet secondaire observed even after 5–6 weeks of administration," adding, "We expect it to fulfill the unmet medical needs of existing drugs that required long-term administration."
De plus, RudaCure is preparing a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for essais cliniques de Phase 2, targeting IND submission by the end of cette année or early l'année prochaine.
RudaCure was founded in 2018 by Professeur Yongho Kim of Gachon University College of Medicine and raised KRW 6 billion through Series A in May. In addition to RCI001, RudaCure is actuellement conducting recherche préclinique on TRPV1 antagonist 'RCI002' as a douleur neuropathique treatment.
